SCHEMBL5651783

SCHEMBL5651783

CON(C)C(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 1/20 0.38
TRPM8 Q7Z2W7 2/20 0.37
ALDH1A1 P00352 7/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PLA2G1B P04054 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
KMT2A Q03164 6/20 0.34
HPGD P15428 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 5/20 0.34
KDM4E B2RXH2 1/20 0.34
PRNP P04156 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALOX5 P09917 1/20 0.33
THRB P10828 1/20 0.33
ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647917 0.88 ALOX5 (0.41) ALDH1A1LMNAMAPTKMT2AHPGD
SCHEMBL5650705 0.83 KMT2A (0.43) ALDH1A1LMNAMAPTKMT2AHPGD
SCHEMBL5651227 0.83 ALDH1A1 (0.47) ADORA2BALDH1A1LMNAMAPTKMT2A
SCHEMBL2949462 0.81 ADORA2B (0.38) ADORA2BTRPM8ALDH1A1LMNAMAPT
SCHEMBL5649654 0.81 ALDH1A1 (0.44) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL5652629 0.80 PLK1 (0.41) ALDH1A1LMNAMAPTKMT2AHPGD
SCHEMBL5650136 0.80 MAPT (0.51) TRPM8ALDH1A1LMNAMAPTKMT2A
SCHEMBL5652095 0.78 HPGD (0.45) ALDH1A1LMNAMAPTKMT2AHPGD
SCHEMBL5649437 0.77 HPGD (0.44) ALDH1A1LMNAMAPTKMT2AHPGD
SCHEMBL5648881 0.77 KMT2A (0.37) ALDH1A1MAPTKMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ADORA2B 709/4885TRPM8 4321/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.